Evidence Hub

Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection

Hojin Kang, Rin Khang, Sangwoo Ham, Ga Ram Jeong, Hyojung Kim, Minkyung Jo, Byoung Dae Lee, Yun Il Lee et al.

Oncotarget, 2017

70 citations

Abstract

// Hojin Kang 1,2,* , Rin Khang 1,2,* , Sangwoo Ham 1,* , Ga Ram Jeong 3 , Hyojung Kim 1 , Minkyung Jo 1 , Byoung Dae Lee 3 , Yun Il Lee 4 , Areum Jo 1,2 , ChiHu Park 5,6 , Hyein Kim 1,5 , Jeongkon Seo 7 , Sun Ha Paek 8 , Yun-Song Lee 1 , Jeong-Yun Choi 1 , Yunjong Lee 1 and Joo-Ho Shin 1,2 1 Department of Molecular Cell Biology, Division of Pharmacology, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute, Suwon, South Korea 2 Single Cell Network Research Center, Sungkyunkwan University School of Medicine, Suwon, South Korea 3 Department of Neuroscience, Department of Physiology, Neurodegeneration Control Research Center, Kyung Hee University School of Medicine, Seoul, South Korea 4 Department of New Biology, Daegu Geongbuk Institute of Science and Technology, Daegu, South Korea 5 Research Core Facility, Sungkyunkwan University School of Medicine, Samsung Biomedical Research Institute, Suwon, South Korea 6 HuGeX Co., Ltd. Seongnam, South Korea 7 UNIST Central Research Facility, Ulsan National Institute of Science and Technology, Ulsan, South Korea 8 Department of Neurosurgery, Seoul National University College of Medicine, Seoul, South Korea * These authors have contributed equally to this work Correspondence to: Yunjong Lee, email: // Joo-Ho Shin, email: // Keywords : metformin, dopaminergic, Parkinson’s disease, PGC-1α, mitochondria, Gerotarget Received : October 10, 2016 Accepted : April 24, 2017 Published : May 24, 2017 Abstract Progressive…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free